Company intelligence
Biocartis
High precision diagnostics for personalized medicine
About Biocartis
Biocartis is an innovative molecular diagnostics company committed to revolutionizing molecular testing with its unique proprietary Idylla™ Platform. We provide next generation diagnostic solutions, aimed at improving clinical practice for the benefit of patients, clinicians, payers and the healthcare industry, with a focus in oncology. Today, Biocartis offers tests supporting melanoma, colorectal, lung, breast, thyroid, brain and blood cancer. Biocartis NV is privately held and headquartered in Mechelen, Belgium.
Verified activity
Signals from Biocartis
20 published signals
Presence & Recognition
Biocartis will be exhibiting the fully automated Idylla platform at the European Society of Pathology Congress in Stockholm, Sweden from 12 to 16 September 2026.
Reported by Biocartis
Presence & Recognition
Biocartis is exhibiting at booth #423 at ECP 2026 in Stockholm, showcasing the Idylla platform for molecular testing.
Reported by Mike Musgnug
Research & Knowledge
Biocartis published a study by Vivek Subbiah, MD and Razelle Kurzrock in JCO journals for the American Society of Clinical Oncology (ASCO) showing that universal germline testing for colorectal cancer patients is needed.
Reported by Ed Esplin, MD, PhD, FACMG, CGAF, FACP
Research & Knowledge
Biocartis published a study by Pedro Uson, MD et al in the American Gastroenterological Association (AGA) showing that universal germline genetic testing is needed to win the war against cancer.
Reported by Ed Esplin, MD, PhD, FACMG, CGAF, FACP
Research & Knowledge
Biocartis published a study by Ed Esplin, MD, PhD, FACMG, CGAF, FACP et al in JCO journals showing that universal germline and tumor genomic testing is needed to win the war against cancer.
Reported by Ed Esplin, MD, PhD, FACMG, CGAF, FACP
Research & Knowledge
Biocartis published a study by Alessandro Mannucci et al. in The Lancet Gastroenterology & Hepatology showing that germline genetic testing results for colorectal cancer patients are clinically informative up to 67 years of age.
Reported by Ed Esplin, MD, PhD, FACMG, CGAF, FACP
Research & Knowledge
Biocartis published a meta-analysis showing that 15% of unselected colorectal cancer patients had germline genetic testing results with positive viral status, with 15.2% of early-onset CRC patients having positive viral status, and 13% of late-onset CRC patients having positive viral status.
Reported by Ed Esplin, MD, PhD, FACMG, CGAF, FACP
Research & Knowledge
Biocartis identified clinically significant findings in 70% of patients with colorectal cancer in an extension of the INTERCEPT trial, including Early Onset CRC and Early Stage CRC, using Universal paired GGT and CGP.
Reported by Ed Esplin, MD, PhD, FACMG, CGAF, FACP
Research & Knowledge
Biocartis combined Universal paired GGT and CGP increases clinical utility for Early Onset and Early Stage CRC patients.
Reported by Ed Esplin, MD, PhD, FACMG, CGAF, FACP
Research & Knowledge
Biocartis highlights the Idylla™ POLE-POLD1 Mutation Assay and Idylla™ MSI Assay as research tools supporting standardized molecular profiling.
Reported by Biocartis
People
Biocartis welcomed Cedric Hahn, PhD, who moved his family across the Atlantic to help grow the US business after joining in August 2022.
Reported by Petra Verlaak
People
Biocartis welcomed Cedric Hahn, PhD, who joined the company in Germany in August 2022 as a Product Specialist.
Reported by Petra Verlaak
People
Biocartis promoted Cedric Hahn to Key Account Manager in January 2024 and then to Director of Strategic Accounts in April 2025.
Reported by Petra Verlaak
Research & Knowledge
Biocartis published a study by Antón-Peñalver et al. (2026) evaluating the use of the Idylla MTS assay on residual liquid-based cytology samples from EUS-FNA specimens in pancreatic cancer.
Reported by Biocartis
Research & Knowledge
Biocartis published a study in the International Journal of Molecular Sciences testing the Idylla IDH1-2 assay across 106 patient samples spanning glioma, cholangiocarcinoma, chondrosarcoma, breast cancer, and acute myeloid leukemia.
Reported by Mike Musgnug
Research & Knowledge
Biocartis published a study in JAMA Cardiology by Lisa DellefaveCastillo et al on the assessment of the diagnostic yield of combined cardiomyopathy and arrhythmia genetic testing.
Reported by Ed Esplin, MD, PhD, FACMG, CGAF, FACP
Research & Knowledge
Biocartis published a study in JACC Journals on 1,013 Brazilian adults with heart failure and ejection fraction ≤50% who had pathogenic/likely pathogenic variants on germline genotyping considered causal.
Reported by Ed Esplin, MD, PhD, FACMG, CGAF, FACP
Research & Knowledge
Biocartis published a study in JACC Journals by Isabella Lima et al on the diagnostic yield of combined cardiomyopathy and arrhythmia genetic testing.
Reported by Ed Esplin, MD, PhD, FACMG, CGAF, FACP
Research & Knowledge
Biocartis released the Idylla™ IDH1-2 Mutation Assay Kit (RUO*) for detecting 5 mutations in the IDH1 gene and 10 mutations in the IDH2 gene.
Reported by Biocartis
Research & Knowledge
Biocartis published a study in Cancer Research Communications combining spatial gene expression with Imaging Mass Cytometry on colorectal liver metastasis tissue to reveal key checkpoint proteins and immune cell recruitment signals.
Reported by Mike Musgnug